Cost-effectiveness analysis of NOVEL therapies for HER2+ metastatic breast cancer- [FAM-] trastuzumab deruxtecan versus tucatinib trastuzumab and capecitabine
Authors:
Vondeling G, Palaka E, Livings C, Naik J and Sullivan W
Publication type:
Conference Proceedings – Poster
Publication Name:
Virtual ISPOR Europe 2020
Citation:
Vondeling G, Palaka E, Livings C, Naik J and Sullivan W. Cost-effectiveness analysis of NOVEL therapies for HER2+ metastatic breast cancer- [FAM-] trastuzumab deruxtecan versus tucatinib trastuzumab and capecitabine. Virtual ISPOR Europe 2020. 16-19 November 2020. Poster PCN141.
